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Abstract
Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and 
development remains largely uncoordinated and fragmented. The current window of opportunity for large scale 
funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused 
by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders 
are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted.
The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of 
stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the 
recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global 
discovery agenda in the coming decade.
The Challenge
On October 17th 2007, Bill & Melinda Gates called on the
global malaria community to embrace "an audacious
goal--to reach a day when no human being has malaria
and no mosquito on earth is carrying it" [1]. This call has
re-energized the global commitment on malaria, building
on previous initiatives, such as the WHO Roll Back
Malaria Initiative. In Europe, the need to address com-
municable diseases linked to poverty has been recognized
in several European Union Framework Programmes
starting with FP5 in 2003, and subsequently FP6 and FP7.
A strong focus on anti-malarial R&D was recognized at
an early stage as a critical component of these pro-
grammes. The RBM Partnership's Global Malaria Action
Plan also emphasized the need for an R&D agenda [2],
which subsequently led to the launch of the MalERA Ini-
tiative [3]. MalERA is a process to identify R&D priorities
that will be required to meet the needs of malaria elimi-
nation. For anti-malarial drugs, it attempts to redirect
some of the R&D efforts from a short-term focus on
malaria control agents towards drugs that will be more
appropriate for elimination programmes [4].
Funding bodies consider many factors when deciding
how to allocate their scarce resources. Important factors
include (i) how the work will fit into a wider global
research agenda, (ii) how this research agenda is respond-
ing to the needs of the disease endemic countries, and
(iii) how their support is seen to be contributing in a pos-
itive and visible way to a broader global plan. The global
agendas are often laid out in general and broad terms,
sometimes lacking technical specificity and detail. They
m a y  a l s o  b e  t o o  n a r r o w  i n  s c o p e  a n d  f a i l  t o  i d e n t i f y
underlying obstacles (e.g. lack of suitable platform tech-
nologies) to progress in a particular field. Funders can
benefit from detailed action plan proposals with input
from all other stakeholders (endemic countries, research-
ers, policy makers, etc.) that allow them to set priorities
with access to more information and context.
Agreed plans and strategies for anti-malarial drug R&D
are essential communication tools for the community to
interact with policy makers and funding bodies. There
needs to be a constant dialogue, based on well-articulated
arguments, in order to ensure that adequate resources
continue to be made available and that they are targeted
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to bring maximum impact. Two rationales for maintain-
ing support to drug R&D are the continuing need for new
drugs and the need to remove obstacles to drug discov-
ery.
Continuous need for new drugs
One of the challenges for malarial drug R&D is to ensure
sustained support even as the current efforts to control
the disease start to show signs of success. In addition,
better diagnosis will probably detect a drop of clinical
cases, especially in sub-Saharan Africa. The new WHO
recommendations to ensure that no treatment is given
without a prior positive diagnosis through microscopy or
RDTs will accelerate this trend [5,6]. The hope is that the
positive outcome of a large reduction in cases will not
l e a d  p o l i c y  m a k e r s  t o  f e e l  p r e m a t u r e l y  t h a t  t h e  w a r
against malaria is being won with the current tools and,
therefore, resources can be redirected to other priorities.
This was the mistake made for tuberculosis R&D with the
roll-out of DOTS (Directly Observed Therapy - Short
Course). The price that is now being paid is the scarcity of
new drugs that are needed to meet the challenges of mul-
tidrug resistant and extensively drug resistant tuberculo-
sis. The changing global environment for malaria control
and elimination and its associated R&D must be con-
stantly communicated to funding agencies and policy
makers to ensure that discovery activities are not de-pri-
oritized. This continuing need can be justified on several
grounds:
Resistance
The Plasmodium parasite continues to show a remark-
able ability to develop resistance to new agents, despite
efforts to find ways to minimize the risk [7]. The develop-
ment and adoption of ACT (artemisinin-containing com-
bination treatment) as first-line therapy for acute cases
has been a major step forward in combating this problem
[8]. It has also highlighted the potential utility of future
new combinations that contain two or three complemen-
tary drugs with different modes of action (with or with-
out an artemisinin component). Recent concerns in
Cambodia about the loss of efficacy of artemisinins
underlines the ability of the parasite to respond to new
agents [9]. It also shows that the global malaria commu-
nity cannot afford to assume that once it has a highly
effective tool (such as ACT) this will reduce the need for
new drugs with novel mechanisms of action to meet
future (if not yet identified) resistance problems.
There is also the need to recognize that the problem of
resistance is not only restricted to Plasmodium falci-
parum, as illustrated by the recent identification of evolv-
ing resistance of Plasmodium vivax to both chloroquine
and primaquine [10]. There is a need to increase the pri-
ority of finding new drugs to tackle these problems if
vivax as well as falciparum malaria is to be controlled and
eliminated.
Improving drug profiles
As malaria control and elimination programmes become
more extensive and sophisticated, the profiles of the
drugs needed for these programmes will change. As the
community develops more integrated ways of delivering
drugs treatment, the profiles of the drug combinations to
be used in these systems have to adapt to the needs of
these programmes. For example, the opportunities to
deliver IPT (intermittent preventive treatment) alongside
other interventions like childhood vaccination, school-
age de-worming, maternal prenatal clinic visits, or bed
net distributions, lead to an unmet need for new drug
combinations that can be delivered in a single treatment
(also possibly directly observed). Similarly, as the priority
of treating the dormant liver stages of vivax malaria
increases in malaria programmes outside sub-Saharan
Africa, the profile of primaquine has been shown to be
unsuitable and the need for a drug with a shorter dosage
regimen increases [11]. The Medicines for Malaria Ven-
ture (MMV) and others are working to ensure that the
malaria community has up-to-date and generally agreed
target product profiles (TPPs) available to work towards
[12,13].
Changing objectives
Until quite recently, the focus of the global drive to con-
trol malaria has been on Plasmodium falciparum. This is
understandable. Falciparum malaria is the major killer
globally, notably of children and pregnant women, and it
is the species that has given the most problems from the
development of resistance. Now that global efforts
against malaria are beginning to move beyond control to
elimination, more emphasis has to be placed on Plasmo-
dium vivax infections and developing agents that can be
used against this species, especially in areas of mixed
vivax and falciparum infections. Where elimination can
be considered, then the removal of asymptomatic reser-
voirs of infection must also be considered. New agents
that can be used in mass drug administration campaigns
or other approaches are needed. All these changes in the
objectives of delivering anti-malarial drug therapy under-
line the need for a continuing high level of investment in
new drug R&D.
Importance of other Plasmodium species
Another risk that must be recognized, as the control of
Plasmodium falciparum and  Plasmodium vivax
improves, is the increase in importance of Plasmodium
species that are currently seen as minor problems. The
removal of falciparum and vivax may open up environ-
mental gaps into which other species can enter. This will
increase the need for drugs that are highly effectiveBoulton et al. Malaria Journal 2010, 9:202
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against other malarial species, for example Plasmodium
malariae, Plasmodium ovale, and Plasmodium knowlesi.
I t  is  not  curr e n t ly  c l ea r if  drugs  wit h m odes  of  a ct ion
effective against vivax or falciparum will be adequately
effective against these species once the competitive pres-
sure of the major parasite species is removed.
Increasing volumes of data
The pharmaceutical industry and other groups are releas-
ing data on the structures of positive hits against Plasmo-
dium derived from high throughput screening. This
major initiative - facilitated by MMV - will give the
malaria R&D community a vast number of structures to
investigated. Two groups have already published large
datasets of screening hits [14,15]. However, experience
tells us that many of these structures will not be "drugga-
ble" as their activity against the parasite in an in vitro situ-
ation will not survive absorption or metabolism in a
h u m a n  h o s t .  M a n y  s t r u c t u r e s  w i l l  a l s o  b e  t o o  c l o s e l y
related to currently identified molecules and so will prob-
ably not have the different modes of action to meet the
target profiles required in the current era. Finally, there is
a  gr ea t  ris k t ha t  t his la r ge  a m oun t  of  da ta wil l no t be
properly prioritized and utilized. Too many groups may
focus on a limited number of the most superficially
promising structures and there will be unnecessary dupli-
cation of effort. This challenge will be exacerbated by a
lack of transparency on who is working on which groups
of molecules. The challenge will be to turn this volume of
data into useful information about the molecules and
who is working on them. This will help research groups
and funders to make informed decisions on the most effi-
cient way to use this information to design their research
programmes and set their priorities.
Obstacles to new drug discovery
Recently, attention is directed towards identifying mole-
cules or modes of action that would be of potential value
in the future fight against malaria. However, in compari-
son, there is less attention towards identifying potential
methodological or platform technological obstacles to
optimize the discovery process. For example, lack of
screening methods (by parasite lifecycle stage or species),
capacity in key elements of the discovery process (such as
medicinal chemistry and predictive in vivo models), or
understanding of the underlying biology, can all slow
down or stall efficient drug discovery. These obstacles are
not always given the priority they deserve when funding
agencies make decisions on allocating resources. There is
an understandable desire to get involved immediately in
working with molecules and testing them against avail-
able models, rather than to develop better models or
other less appealing, but necessary technologies or back-
ground scientific understanding. An additional roadblock
to discovery is the concentration of relevant expertise and
development organizations in the North with signifi-
cantly less critical mass in disease endemic countries.
Through structured co-operative initiatives it should be a
possible to redress this imbalance.
CRIMALDDI
The CRIMALDDI Consortium has been set up with a
two-year EU Seventh Framework Programme grant [16].
Its objective is to help develop a framework that attempts
to address the fragmented and often uncoordinated R&D
initiatives in anti-malarial drug discovery and develop-
ment. By bringing together experts (both from within the
malaria world and outside) - through an integrated and
logical series of meetings, conferences, and workshops -
detailed recommendations on how to address some key
priority challenges will be developed and then dissemi-
nated. Particular attention will be given to support lead-
ing European malaria research initiatives and partners to
coordinate better their efforts. The Consortium aims to
work in close collaboration with all relevant stakeholders
(including funding bodies, academic research groups, the
pharmaceutical industry, and policy makers both in
malaria endemic and non-endemic countries). The Con-
sortium will also aim to coordinate these efforts with
international ones, attempt to engage the pharmaceutical
industry, try to contribute towards the discussions on set-
ting global research priorities, and give some input to the
preparation of the European "anti-malarial drug" research
agenda for the next decade. The work of the Consortium
will focus on drug discovery and frameworks for transla-
tional research partnerships with organizations and
endemic countries, as well as implication of these on drug
development for sustained control and elimination. It is
looking to make recommendations that will make a
noticeable impact in the next decade. It is formulating its
recommendations both around the continuing need for
new drugs and the need to remove obstacles to drug dis-
covery.
Structure
The Consortium consists of nine participating institu-
tions involved in anti-malarial drug discovery (see Table
1). The PIs representing each institutions form the Con-
sortium Management Committee. The Management
Committee is responsible for setting the workplan, iden-
tifying the priority challenges for in-depth analysis and
recommendations, and overseeing the development of
the outputs and proposals to the global community.
The composition of the Consortium is drawn from
European and African based institutions. In order to
avoid taking too parochial view of the challenges con-
fronting anti-malarial drug discovery or unduly focusing
on their particular research priorities, the work of theBoulton et al. Malaria Journal 2010, 9:202
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C o n s o r t i u m  i s  a l s o  s u b j e c t  t o  e x t e r n a l  r e v i e w  b y  a n
Expert Advisory Group (EAG). The EAG consists of key
global opinion leaders in the field of anti-malarial drug
discovery and development who are able to comment on
the CRIMALDDI proposals both from the R&D and pol-
icy-makers' perspective. Its terms of reference are
designed to ensure that the methodology and the recom-
mendations of the Consortium are aligned with discus-
sions by other similar agenda-setting initiatives and do
not take too Eurocentric a view of the challenges. It
enables the Consortium to co-ordinate its findings with
other groups (especially MalERA). At its first meeting,
the Management Committee of the Consortium identi-
fied the areas of expertise that it felt should be included in
the EAG. It then identified appropriate experts to be
invited who met these requirements and who would
bring a wider geographical perspective to the Consor-
tium's thinking. The EAG has met once and there are
plans to meet twice in 2010.
Methodology and work to-date
The basic approach of the project in arriving at its recom-
mendations for the malaria community's consideration is
to bring together global experts in a series of one- or two-
day workshops. The starting point of each workshop is a
d e t a i l e d  q u e s t i o n  t h a t  t h e  p a r t i c i p a n t s  c a n  r e f i n e  a n d
then will use to develop interactively a set of detailed and
action oriented recommendations designed to answer the
question. One of the objectives of the Consortium is to
try to bring new thinking from other fields of drug dis-
covery to address the challenges that have been identi-
fied. It is hoped that the workshops will be able to find
lessons from related fields (e.g. liver immunology in can-
cer, stem cell research, other infectious diseases) that may
offer new insights worth pursuing in addressing the more
intractable challenges found in malaria.
The overall process for the work of the Consortium is
shown in Figure 1. The Consortium Management Com-
mittee has already met twice to identify the priority areas
of focus for the Consortium (workstreams). The first
meeting attempted to establish both the range of drug
discovery and platform technology work required to
meet the evolving needs for new anti-malarial drugs and
the actual work being undertaken around the world. This
then allowed the team to carry out a detailed gap analysis.
At its second meeting, the team then grouped the gaps
into logical workstreams, which could be possible topics
for the focused workshops planned for 2010. The various
workshop topics were then prioritized based on their
importance to increasing the productivity of drug discov-
ery and the degree of unmet need the Committee felt
existed and the top five selected for further work (Table
2). Other topics considered are listed in Table 3. The
rationale for addressing only the top five issues at this
stage is presented. All this work was then subjected to
review by the EAG before being taken further.
The thinking of the Consortium members (endorsed by
the EAG) in arriving at these five workshop topics can be
summarized as follows:-
Workshop 1 ("P. falciparum and P. vivax novel targets
and classes"): despite efforts to identify novel targets and
chemotypes, much anti-malarial drug discovery is still
focused on a few well-established and well-characterized
groups (e.g. anti-folates, DHODH) and primarily on the
blood stage of the parasite's life cycle. Are there ways to
accelerate the identification of novel targets and drug
classes that act elsewhere?
Workshop 2 ("Managing the wealth of new HTS data"):
various research groups and pharmaceutical companies
are placing data on large numbers of positive hits from
whole cell malaria parasite high throughput screening
into the public domain. However, there is a risk that there
may not be adequate systems in place to allow this data to
be turned by interested groups into meaningful informa-
tion to support drug discovery. Are there one or more
approaches to making this data available that will make it
more useful and user-friendly to the wider malaria com-
munity?
Table 1: CRIMALDDI Consortium Membership
Participating Institution Principal Investigator
Liverpool School of Tropical 
Medicine
Prof Steve Ward
WHO/TDR Dr Solomon Nwaka
Medicines for Malaria 
Venture
Dr Ian Bathurst
University of Heidelberg Prof Michael Lanzer
University of Milan Prof Donatella Taramelli
Centre National de la 
Recherche Scientifique 
(CNRS)
Prof Henri Vial
Inserm (Inserm-EPFL Joint 
Laboratory)
Prof Christian Doerig
University of Buea Prof Simon Efange
(also representing ANDI*)
University of Cape Town Prof Kelly Chibale
(also representing ANDI*)
Consortium Co-ordinating 
Office
Mr Ian Boulton Project Manager & Facilitator
Ms Susan Jones EU Project Manager
Ms Tracy Seddon Administrator
* ANDI is an initiative to promote & sustain African-led R&D 
innovation through the discovery, development, and delivery of 
affordable new tools including those based on traditional 
medicines [18].Boulton et al. Malaria Journal 2010, 9:202
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Workshop 3 ("Artemisinin resistance"): since the identi-
fication of resistance to artemisinins in Cambodia, most
of the research work on this topic has been focused on
finding ways to prevent its spread outside the limited area
where it is currently found. However , it is still unclear
what the exact mechanism of this resistance is and the
degree to which it may cause resistance to newer perox-
ide drug candidates. Is it possible to design an integrated
research programme that will not only identify the mech-
anism of the resistance, but be able to be predictive of
cross-resistance and also allow strategies to be developed
to minimize its spread and preserve existing artemisinin-
containing drugs?
Workshop 4 ("Stage-specific screening methods"): one
of the barriers to anti-malarial drug discovery is the lack
of robust screening methods that can be replicated by
laboratories across the world. It is not possible to screen
properly against all species of the human malaria para-
site, or for activity against stages of the life cycle other
than Plasmodium falciparum blood stage. Is it possible to
develop recommendations on the priorities for research
into new screens that are stage specific and can reliably
identify species other than P. falciparum?
Workshop 5 ("Using chemistry to understand biology"):
there is a large amount of information now available on
the chemical structures that show activity against Plas-
modium in whole cell screens. It ought to be possible to
use information on the chemical structures that show
activity to draw conclusions on the underlying parasite
biology that is being targeted. What would a research
programme to identify the biological processes that are
being interrupted by the active chemotypes look like and
what would need to be in place to support such a pro-
gramme?
The next stage of the process will be to hold workshops
to design detailed and action-oriented work plans to
address the key issues identified. These workshops will be
one or two days in duration. The Consortium will invite
10 to 20 global experts in the particular field of the ques-
tion, but it will aim not to draw solely on experts from
within the malaria community. Efforts will be made to
bring in outside expertise that can bring new thinking on
existing problems (e.g. what can be learned on issues of
resistance from the anti-bacterial and anti-viral world).
The selection of participants for the workshops is being
made by the Workshop Leaders in consultation with the
rest of the Management Committee and the EAG. They
will attempt to identify global experts with the key skill
sets and expertise to address in depth the topic of each
Workshop. These workshops will be facilitated in order
Table 2: Five priority workstreams
Workstream No. Short Name Workshop Question
1 Pf & Pv novel targets & classes How to identify and exploit novel targets at all stages of the lifecycle of 
P falciparum & P vivax.
2 Managing the wealth of new HTS data Given the large number of molecular structures that have given 
positive hits in the HTS screens and which are now being released, how 
to develop systems to:-
Make the information available to the community in an accessible 
way;
Filter the structures with robust methods to identify those 
structures which are druggable and more promising starts for lead 
optimization;
Allow the community to know who is working on which structures 
so that duplication can be avoided and resources not 
unnecessarily wasted.
3 Artemisinin resistance How to identify the mechanism(s) of artemisinin resistance in order to 
be able to design strategies to overcome or avoid it through novel 
combinations or novel molecular designs that counter the 
mechanism(s).
4 Stage-specific screening methods How to develop a complete set of robust and replicable screening 
methods that can be used to screen novel compounds for efficacy 
against the various stages of the Plasmodium parasite lifecycle.
5 Using chemistry to understand biology How to use the results of the whole cell screening of compounds for 
anti-malarial activity as a way of gaining insights into the underlying 
targets of different drug classes and then use this information to 
identify novel targets.
The five priority workstreams identified by the Consortium's analysis to-date and endorsed by the EAG.Boulton et al. Malaria Journal 2010, 9:202
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to ensure maximum interactivity and to keep the meeting
focused on the specific question identified for analysis.
The detailed questions to be addressed at the five priority
workshops are shown in Table 2. If the workshops alone
are not enough to develop adequate recommendations to
the satisfaction of the participants, then consideration
w i l l  b e  m a d e  t o  h a v i n g  a d d i t i o n a l  m e e t i n g s  o r  o t h e r
forms of collaborative discussions to enable quality
answers to the workshop questions to be agreed upon.
The outputs from the workshops will then be consoli-
dated with the help of the EAG for publication at the end
of the project. This will allow the recommendations to be
available to the malaria community as one input to the
agenda setting mentioned earlier in this paper.
The CRIMALDDI Consortium is aware of the need to
align and coordinate its efforts with those of other related
initiatives, most notably the Global Malaria Action Plan
and MalERA. The presence of MMV and TDR as Con-
sortium members is intended to ensure good coordina-
tion with existing efforts. The Chair of the Drug
Discovery Workstream of MalERA is a member of the
EAG. Members of the Consortium have also participated
in meetings of the MalERA Drugs Consultative Group.
As mentioned elsewhere, MalERA's focus is broad, high-
level, and medium to long-term. CRIMALDDI's focus is
on a few key priority areas where it plans to go in depth
into their needs and where the impact can be seen in the
next decade. Therefore the two initiatives are comple-
mentary.
Community involvement and communications
The Consortium is well aware that it must try to gather
input from as wide a range of stakeholders as possible.
Formally it can rely on input from the members of the
Consortium, the EAG, and the participants in the five
workshops. They represent not only five European and
two African leading drug discovery research centres in
the Consortium. They also include key international
organizations (TDR), funders (e.g. Bill and Melinda Gates
Foundation, Wellcome Trust, MMV), major institutions
(e.g. London School of Hygiene and Tropical Medicine,
Institut Pasteur, Columbia University, Swiss Tropical and
Public Health Institute), and the pharmaceutical industry.
The geographical reach of the input covers not only Euro-
pean and African based institutions and organizations,
but also ones based in India, South East Asia, and North
America.
However the Management Committee decided at its
first meeting that it needed to try to gather as wide range
of input as possible from the anti-malarial community. To
Table 3: Workstreams Not Prioritized at this Stage
Workstream Reason for not prioritizing at this stage
Novel combinations Would first require the identification and 
development of new chemotypes from 
which to design appropriate novel 
combinations
Natural products Considered an important route to 
identifying new drugs but would require 
broader discussion with experts 
specializing in this field than is possible in 
the first phase of the work of CRIMALDDI.
Novel drugs for severe 
malaria
Need appropriate models to study. Also 
likely that a first step would be to identify 
novel chemotypes and then compounds 
with the appropriate PK/PD properties for 
severe malaria.
Novel drugs for malaria 
in pregnancy
Need appropriate models to study. Also 
likely that a first step would be to identify 
novel chemotypes and then compounds 
with the appropriate PK/PD properties for 
malaria in pregnancy.
Drugs for mass 
administration
Starting point would be novel 
chemotypes from which drugs with 
appropriate efficacy & safety profiles can 
be identified.
Drugs to overcome 
resistance mechanisms 
(non-artemisinin)
The development of novel chemotypes 
would, by definition, identify molecular 
frameworks that could overcome 
resistance by different mechanisms. A 
specific effort to find molecules of the 
same class to overcome resistance would 
not be the most productive way forward.
These equally important workstreams were not included in this 
phase of the project for the reasons explained in the table. However, 
the Consortium or others may address them in the future.
Figure 1 CRIMALDDI Work Process. The CRIMALDDI process is a log-
ical and structured analysis of the challenges to novel anti-malarial 
drug R&D with the objective of delivering detailed action plans to ad-
dress the priority challenges. The steps are (1) to identify the work 
needed to meet the GMAP objectives for drug treatment in both the 
Control & Elimination phases of the Plan: (2) identify the work currently 
being undertaken around the world and where there are gaps with the 
work needed: (3) prioritize the R&D efforts needed to fill the gaps, es-
pecially drug discovery and the development of platform technolo-
gies: (4) work with other experts to develop detailed action plans to fill 
the priority gaps: (5) consolidate the recommended action plans and 
publish them.
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this end it has set up a website [17] where anyone will be
able to view the outputs of the work to-date and to com-
ment both on the outputs and on specific questions
posed by the Consortium through the site's discussion
forum. The members of the Consortium have and will
continue to take every opportunity to raise the awareness
of its work at relevant meetings (e.g. MIM Conference in
Nairobi, November 2009).
The website will include detailed summaries of the
work concluded to-date as well as the plans for the next
steps. Minutes of the EAG will also be posted. In addi-
tion, the Consortium will publish summaries of the con-
clusion of the workstreams as they become available. Key
issues that are raised at the workshops will be placed into
the discussion section of the website so that non-partici-
pants in the workshops will have an opportunity to make
their own comments. These will be taken into consider-
ation when the final recommendations are written up.
The Consortium plans to present its overall conclusions
and recommendations at a major conference in late 2010
or early 2011.
Conclusions
It is clear that the current window of opportunity of large
scale resourcing for anti-malarial drug R&D will not last
and that resources might become much more con-
strained over the next decade. It is vital to ensure that
stakeholders worldwide are given clear and logical guid-
ance on the priorities for such R&D. Research groups will
then be able to take their cue from these priorities in
deciding on the field of work they would like to engage in.
It is hoped that this will ensure that the new anti-malarial
drugs needed to meet the challenge of control, elimina-
tion, and eradication are developed in an efficient and
logical manner. Long-term and broad ranging strategic
plans (such as GMAP and MalERA) will be of great value
in making clear the breadth of challenges to be addressed
and identifying how the focus of the research agenda
needs to be adapted over time. However, they will of
necessity be high-level and may lack the technical detail
that will help in establishing priority work plans needed
to coordinate properly the R&D efforts in the coming
decade. The CRIMALDDI Consortium is an initiative
that is intended to contribute to the research agenda set-
ting by making recommendations on a few key near-term
priority needs so, it is hoped, anti-malarial R&D can pro-
ceed in the most efficient and effective way. It will
develop recommendations for these priorities that may
be then used to guide and coordinate the efforts, espe-
cially (but not exclusively) in Europe. Through the devel-
opment of detailed and prioritized recommendations, it
is hoped that the output of the Project will be a valuable
tool for funding agencies and other stakeholders to set
their priorities for drug discovery. The eventual realiza-
tion of these priorities will require appropriate collabora-
tive frameworks including participation of researchers
from the global community incorporating malaria-
endemic countries.
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Eradication Research Agenda; MIM: Multilateral Initia-
tive on Malaria; MMV: Medicines for Malaria Venture;
PI: Principal Investigator; RBM: Roll Back Malaria; RDT:
Rapid Diagnostic Test; TDR: UNICEF/UNDP/World
Bank/WHO Special Programme for Tropical Disease
Research & Training; TPP: Target Product Profile.
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